JAK3 and non-small cell lung carcinoma: To further investigate the involvement of JAK3/STAT5 pathway in enhancing the role of cisplatin sensitivity of NSCLC cells by IL‐7, a novel JAK3 inhibitor was used to inhibit the JAK3 pathway.